Johnson & Johnson

22 hours ago · 247wallst.com

Some dividend stocks cut payouts the moment a recession hits, but a small group of blue chips kept raising theirs through the 2008 financial crisis and the 2020 shutdowns.

1 day ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart pumps are used to support a patient's heart during and after high-risk percutaneous coronary intervention (HRPCI). Real-world and observational registry data from 1,379 HRPCI patients across hospitals in the U.S. and E.

2 days ago · fool.com

Johnson & Johnson is a large medical device and pharmaceutical company. Third-quarter 2026 earnings fell nearly 96% year over year.

2 days ago · zacks.com

J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.

2 days ago · 247wallst.com

On Halloween eve, the scariest thing an income investor can find is a yield that looks generous but is stressed. That is a payout the business can barely fund, and it tends to get cut at the worst moment.

2 days ago · 247wallst.com

Four companies have raised their dividends every single year for at least half a century, but not all of them carry the same risks heading into retirement.

3 days ago · zacks.com

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

4 days ago · seekingalpha.com

Johnson & Johnson reported Q3 revenue of $25.4 billion, supported by Innovative Medicine's 7.9% operational growth, while MedTech lagged at 2.5%. Management raised its 2026 guidance and adjusted EPS. TREMFYA continues offsetting STELARA's decline, generating $2.4 billion in quarterly sales. Recent Ph.3 FUZION data further strengthen its clinical position. MedTech remains a concern, despite Shockwave's 17.2% growth. Weakeness in Surgery, Abiomed, and international markets highlights the need for broader operational improvement.

6 days ago · 247wallst.com

If you are at or near retirement, the dividend that matters most is the one that keeps arriving and keeps growing through recessions, lawsuits and bear markets.

8 days ago · 247wallst.com

Treasury bills are paying rates that beat several household-name dividend stocks right now, but the retiree who chases that yield without reading the fine print may find their income cut in half before the decade ends.